Phase 3 N=128 A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)
Asthma
Primary: Pharmacodynamic Endpoint Post-dose PC20 — 114 mg/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=106 A Clinical Study to Investigate the Long-term Use of Lacosamide as Monotherapy in Subjects Who Completed Study SP0994
Epilepsy
Primary: Percentage of Participants Experiencing Any Adverse Events (AEs) Reported Spontaneously by the Subject and/or Caregiver or Observed by Investigator — 59.4 percentage of…
Phase 3 N=519 To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis
Actinic Keratosis
Primary: Number of Participants With Complete Clearance (Absence) of Actinic Keratosis Lesions as Determined by Visual Inspection of the Investigator — 81; 76; 10 Participants
Phase 3 N=56 Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
Coronary Artery Bypass Grafting · Postoperative Atrial Fibrilation · Stroke
Primary: Number of Participants With Strokes — 0; 0 participants — p=1.0
Phase 3 N=903 Comparative Safety and Bioequivalence of Two Treatments in the Treatment of Acne Vulgaris
Acne
Primary: Mean Percent Change From Baseline to Day 84 in Inflammatory (Papules and Pustules) Lesions — 61.07; 65.58; 41.63 percent change of lesion counts
Phase 3 N=1,180 A Study to Compare Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% to Acanya® Topical Gel in the Treatment of Acne Vulgaris
Acne
Primary: Mean Percent Change in the Inflammatory (Papules and Pustules) Lesion Count — 61.70; 63.89; 42.22 percent change of lesion counts
Phase 3 N=376 Long Term Safety Assessment of SER120 in Patients With Nocturia
Nocturia
Primary: Mean Serum Sodium — -0.0; -0.4; -0.4; -0.3 mmol/L
Phase 3 N=256 Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
Chronic Troublesome Sialorrhea · Cerebral Palsy · Stroke
Primary: Change From Baseline in Unstimulated Salivary Flow Rate (uSFR) at Week 4 — -0.07; -0.14 gram per minute (g/min) — p== 0.0012
Phase 3 N=838 Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
Dermatitis · Dermatitis, Atopic · Eczema
Primary: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and a Reduction of Greater Than or Equal to (>=) 2…
Phase 3 N=1,759 Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12 — 76.6; 69.8; 70.5; 49.9 percentage of…
Phase 3 N=39 A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
Primary Hyperoxaluria Type 1 (PH1)
Primary: Percent Change in 24-hour Urinary Oxalate Excretion Corrected for Body Surface Area (BSA) From Baseline to Month 6 — -11.8; -65.4 percent change — p=<0.0001
Phase 3 N=205 Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
Proliferative Diabetic Retinopathy · Vitreous Hemorrhage
Primary: E-ETDRS Visual Acuity Letter Score (Area Under the Curve From Baseline) — 59.3; 63.0 units on a scale
Phase 3 N=1,539 Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older
Influenza Immunization · Healthy Volunteers
Primary: Geometric Mean Titers (GMTs) of Influenza Antibodies in Participants Aged 60-64 Years and Greater Than or Equal to (>=) 65 Years — 471; 248; 303; 178 titers
Phase 3 N=503 Study to Evaluate Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery
Infections
Primary: Number of Participants In Intent to Treat (ITT) Analysis Set With Superficial and Deep Incisional Surgical Site Infections (SSI) Involving Principal Incision Within 30…
Phase 3 N=463 A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable
Atopic Dermatitis
Primary: Percentage of Participants Achieving Eczema Area and Severity Index 75 (EASI75) (Placebo, 2 mg or 4 mg Baricitinib) — 17.2; 27.6; 31.5 percentage of participants — p=0.071